# A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

> **NCT00501046** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 1015 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** AST-120

## Key facts

- **NCT ID:** NCT00501046
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 1015 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501046, "A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00501046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*